BRIEF — Rezolute Announces Completion Of Enrollment In Phase 3 Uplift Study Of Ersodetug In Tumor Hyperinsulinism

Oct 14 (Reuters) — Rezolute, Inc.: Rezolute Announces Completion Of Enrollment In Phase 3 Uplift Study Of Ersodetug In Tumor Hyperinsulinism Rezolute - Completes Enrollment In Phase 3 Uplift Study; Topline Results Expected Mid-december 2026 Rezolute - Primary Endpoint Is 50% Reduction In Glucose Infusion Rate Within 8 Weeks Rezolute: Plans To Continue Expanded Access Program For Compassionate Use Of Ersodetug In Tumor Hi Source text:... Further company coverage: RZLT.O (((Reuters.Briefs@thomsonreuters.com;));)